Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Bacterial Toxins01:12

Bacterial Toxins

148
Bacterial toxins are sophisticated virulence factors that enable pathogenic bacteria to interact with, invade, and damage host tissues. These toxins fall broadly into two types: protein exotoxins, which are secreted into the environment and target specific host receptors, and lipopolysaccharide endotoxins, which are structural components of the bacterial outer membrane released primarily during bacterial lysis or membrane shedding. Exotoxins generally act more selectively, binding to cell...
148
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report.

Blood neoplasia·2026
Same author

USP40 protects podocytes by deubiquitylating integrin β1.

Biochemical and biophysical research communications·2026
Same author

Targeted delivery of RNA using synthetic bacterial spores.

Journal of drug delivery science and technology·2026
Same author

Recent advances in structural investigations of cancer antigen mesothelin and its interactions with therapeutic antibodies.

Antibody therapeutics·2026
Same author

RO4, a high-affinity humanized antibody against the juxtamembrane region of mesothelin for targeted cancer therapy.

Antibody therapeutics·2026
Same author

Mapping drug distribution using CT imaging following direct tissue injection in ex vivo liver: informing clinical implementation.

CVIR oncology·2025

Related Experiment Video

Updated: May 2, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Immunotoxins for leukemia.

Alan S Wayne1, David J Fitzgerald, Robert J Kreitman

  • 1Children's Center for Cancer and Blood Diseases, Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, The Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA; and.

Blood
|March 1, 2014
PubMed
Summary
This summary is machine-generated.

Monoclonal antibodies show limited efficacy in leukemia treatment. Attaching them to protein toxins creates immunotoxins, which are highly effective against leukemia cells in preclinical and early clinical studies.

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.9K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

6.4K

Related Experiment Videos

Last Updated: May 2, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.9K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

6.4K

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Monoclonal antibodies targeting hematopoietic differentiation antigens are used for hematologic malignancies.
  • Their efficacy as single agents in leukemia treatment is generally limited.
  • Targeting specific antigens on leukemia cells is crucial for effective therapy.

Purpose of the Study:

  • To explore the development and efficacy of immunotoxins for leukemia treatment.
  • To investigate methods for enhancing the potency of monoclonal antibodies against leukemia.
  • To assess the potential of immunotoxins in overcoming the limitations of unconjugated antibodies.

Main Methods:

  • Development of immunotoxins by linking monoclonal antibody binding domains to protein toxins.
  • Utilizing antibody specificity for targeted delivery to leukemia cells.
  • Evaluation of cytotoxicity in vitro, in xenograft models, and in early-phase human clinical trials.

Main Results:

  • Recombinant immunotoxins demonstrate high cytotoxicity against leukemic blasts.
  • Immunotoxins show efficacy in preclinical models and early human trials.
  • The targeted delivery mechanism enhances the anti-leukemic effect.

Conclusions:

  • Immunotoxins represent a potent therapeutic strategy for leukemia.
  • These agents offer improved efficacy compared to unconjugated monoclonal antibodies.
  • Immunotoxins are expected to play a significant role in future leukemia treatment regimens.